Angiogenesis is regulated by the highly coordinated function of various proteins with pro- and antiangiogenic functions. Proangiogenic factors include vascular endothelial growth factor (VEGF), fibroblast growth factor, platelet-derived growth factor, insulin-like growth factor, transforming growth factor, angiopoietins, and several chemokines; antiangiogenic factors include thrombospondin-1, angiostatin, and endostatin. Matrix metalloproteinases display a dual role in vascular development. Notch signaling affects remodeling of the primary vascular network of uniformly sized vessels into functionally and morphologically distinct arteries, veins, and capillaries. Tumors, described as ‘wounds that never heal’, lose the appropriate balance among these factors. Although VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to make additional gains. Here, we highlight recent advances in our understanding of the regulation of tumor angiogenesis and discuss the potential of molecular targeting as a new therapeutic approach.

Keywords:
Stromal cell, Vascular endothelial growth factor, c-Jun N-terminal kinase
1.
Folkman J, Kalluri R: Cancer without disease. Nature 2004;427:787.
2.
Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–739.
3.
Mueller MM, Fusenig NE: Friends or foes – bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839–849.
4.
Budhu A, Forgues M, Ye QH, et al: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99–111.
5.
Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003;9:669–676.
6.
Grothey A, Galanis E: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507–518.
7.
Sakurai T, Maeda S, Chang L, Karin M: Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006;103:10544–10551.
8.
Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007;7:415–428.
9.
Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, Calvo A: VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010;316:554–567.
10.
Grothey A, Ellis LM: Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2008;14:170–177.
11.
Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.
12.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
13.
Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391–400.
14.
Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–134.
15.
Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–124.
16.
Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
17.
Sandler A, Gray R, Perry MC, Brahmer J, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550.
18.
Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
19.
Kudo M, Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010;78(suppl 1):154–166.
20.
Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592–603.
21.
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232–239.
22.
Pàez-Ribes M, Allen E, Hudock J, Takeda T, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220–231.
23.
Huang J, Soffer SZ, Kim ES, et al: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res 2004;2:36–42.
24.
Kerbel RS: Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev 2001;20:1–2.
25.
Shojaei F, Wu X, Malik AK, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911–920.
26.
De Palma M, Venneri MA, Galli R, et al: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211–226.
27.
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91–102.
28.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39–51.
29.
Cao Y, Cao R, Hedlund EM: R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 2008;86:785–789.
30.
Korc M, Friesel RE: The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009;9:639–651.
31.
Maciag T, Mehlman T, Friesel R, Schreiber AB: Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science 1984;225:932–935.
32.
Abraham JA, Mergia A, Whang JL, et al: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986;233:545–548.
33.
Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26–45.
34.
Beenken A, Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009;8:235–253.
35.
Lindner V, Majack RA, Reidy MA: Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004–2008.
36.
Wang D, Huang HJ, Kazlauskas A, Cavenee WK: Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999;59:1464–1472.
37.
Lindahl P, Johansson BR, Levéen P, Betsholtz C: Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242–245.
38.
Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276–1312.
39.
Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350–1358.
40.
Carmeliet P: Angiogenesis in health and disease. Nat Med 2003;9:653–660.
41.
Augustin HG, Koh GY, Thurston G, Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165–177.
42.
Saharinen P, Bry M, Alitalo K: How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 2010;17:198–205.
43.
Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010;16:3618–3627.
44.
Brown JL, Cao ZA, Pinzon-Ortiz M, et al: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145–156.
45.
Hashizume H, Falcón BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010;70:2213–2223.
46.
Oliner J, Min H, Leal J, et al: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507–516.
47.
De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003;9:789–795.
48.
Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231–237.
49.
Pucci F, Venneri MA, Biziato D, et al: A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood ‘resident’ monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009;114:901–914.
50.
Kioi M, Vogel H, Schultz G, et al: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694–705.
51.
Thurston G, Kitajewski J: VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008;99:1204–1209.
52.
Hellström M, Phng LK, Hofmann JJ, et al: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776–780.
53.
Noguera-Troise I, Daly C, Papadopoulos NJ, et al: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032–1037.
54.
Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083–1087.
55.
Zeng Q, Li S, Chepeha DB, et al: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13–23.
56.
Rundhaug JE: Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res 2003;9:551–554.
57.
Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737–744.
58.
O’Reilly MS, Wiederschain D, Stetler-Stevenson WG, et al: Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 1999;274:29568–29571.
59.
Gialeli C, Theocharis AD, Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011;278:16–27.
60.
Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J: The generation of endostatin is mediated by elastase. Cancer Res 1999;59:6052–6056.
61.
Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM: Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172:2853–2860.
62.
Mestas J, Burdick MD, Reckamp K, et al: The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005;175:5351–5357.
63.
Wang D, Wang H, Brown J, et al: CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006;203:941–951.
64.
Luan J, Shattuck-Brandt R, Haghnegahdar H, et al: Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997;62:588–597.
65.
White ES, Flaherty KR, Carskadon S, et al: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res 2003;9:853–860.
66.
Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996;97:2792–2802.
67.
Kitadai Y, Haruma K, Sumii K, et al: Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. Am J Pathol 1998;152:93–100.
68.
Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992–997.
69.
Salcedo R, Ponce ML, Young HA, et al: Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000;96:34–40.
70.
Maione TE, Gray GS, Petro J, et al: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247:77–79.
71.
Gupta SK, Singh JP: Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 1994;127:1121–1127.
72.
Romagnani P, Annunziato F, Lasagni L, et al: Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001;107:53–63.
73.
Streubel B, Chou A, Huber D, et al: Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250–259.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.